Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Yanan Zhu is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/11/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | SYRE | Buy Now | Spyre Therapeutics | $37.98 | 5.32% | $35 → $40 | Maintains | Overweight | Get Alert |
| 05/09/2024 | CRSP | Buy Now | CRISPR Therapeutics | $62.31 | 4.32% | $70 → $65 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | IONS | Buy Now | Ionis Pharmaceuticals | $39.69 | 106.6% | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/22/2024 | ENGN | Buy Now | enGene Holdings | $8.20 | 265.85% | → $30 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | AFMD | Buy Now | Affimed | $6.70 | 273.13% | $30 → $25 | Maintains | Overweight | Get Alert |
| 03/27/2024 | BLUE | Buy Now | bluebird bio | $0.97 | 209.21% | $4 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/05/2024 | MGX | Buy Now | Metagenomi | $6.50 | 284.62% | → $25 | Initiates | → Overweight | Get Alert |
| 03/01/2024 | SYRE | Buy Now | Spyre Therapeutics | $37.98 | -7.85% | $12 → $35 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/01/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $8.87 | 181.85% | $22 → $25 | Maintains | Overweight | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $8.87 | 148.03% | $17 → $22 | Maintains | Overweight | Get Alert |
| 01/03/2024 | RNA | Buy Now | Avidity Biosciences | $28.90 | 73.01% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/02/2024 | VYGR | Buy Now | Voyager Therapeutics | $8.67 | 61.48% | $9 → $14 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/27/2023 | GRCL | Buy Now | Gracell Biotechnologies | — | — | → $10 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/15/2023 | BLUE | Buy Now | bluebird bio | $0.97 | 415.36% | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 11/09/2023 | FATE | Buy Now | Fate Therapeutics | $3.89 | 28.53% | $6 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/16/2023 | AGLE | Buy Now | Aeglea BioTherapeutics | — | — | $8.75 → $12.5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.60 | 566.67% | $5 → $4 | Maintains | Overweight | Get Alert |
| 07/13/2023 | AVRO | Buy Now | Avrobio | $1.50 | 33.33% | $2.5 → $2 | Maintains | Overweight | Get Alert |
| 05/30/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $8.87 | 91.66% | $11 → $17 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/11/2023 | RNA | Buy Now | Avidity Biosciences | $28.90 | 73.01% | $55 → $50 | Maintains | Overweight | Get Alert |
| 03/27/2023 | AFMD | Buy Now | Affimed | $6.70 | 4.48% | → $70 | Assumes | → Overweight | Get Alert |
| 03/27/2023 | TCRT | Buy Now | Alaunos Therapeutics | $1.02 | 194.12% | → $45 | Assumes | → Overweight | Get Alert |
| 03/27/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.40 | 81.82% | → $8 | Assumes | → Overweight | Get Alert |
| 03/27/2023 | FATE | Buy Now | Fate Therapeutics | $3.89 | 54.24% | → $6 | Assumes | → Equal-Weight | Get Alert |
| 03/27/2023 | GRCL | Buy Now | Gracell Biotechnologies | — | — | → $7 | Assumes | → Overweight | Get Alert |
| 03/27/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $8.87 | 24.01% | → $11 | Assumes | → Equal-Weight | Get Alert |
| 03/01/2023 | BEAM | Buy Now | Beam Therapeutics | $24.69 | 325.27% | $125 → $105 | Maintains | Overweight | Get Alert |
| 01/04/2023 | TSHA | Buy Now | Taysha Gene Therapies | $3.72 | 168.82% | $14 → $10 | Maintains | Overweight | Get Alert |
| 01/04/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.60 | 2400% | $20 → $15 | Maintains | Overweight | Get Alert |
| 01/04/2023 | RAPT | Buy Now | RAPT Therapeutics | $3.70 | 1197.3% | $55 → $48 | Maintains | Overweight | Get Alert |
